Characteristics | Values |
---|---|
Age, yrs, mean ± SD* | 15.3 ± 6.9 |
Male:female, n | 3:14 |
Age at JIA diagnosis, yrs, mean ± SD | 3.1 ± 2.1 |
Age at uveitis diagnosis, yrs, mean ± SD | 4.3 ± 2.6 |
ILAR classification | |
Persistent oligoarthritis | 5 (29.4) |
Extended oligoarthritis | 4 (23.5) |
Polyarthritis | 7 (41.2) |
Undifferentiated | 1 (5.9) |
ANA+ | 16 (94.1) |
HLA-B27+ | 2 (11.8) |
RF+ | 0 (0) |
Uveitis type: anterior, no. patients (%) | 17 (100) |
Secondary ocular complications | |
Patients with complications, no. patients (%) | 13 (76.5) |
Cataract | 10 (58.8) |
Band keratopathy | 9 (52.9) |
Synechia | 7 (41.2) |
Ocular hypertension | 4 (23.5) |
Glaucoma | 4 (23.5) |
Macular edema | 5 (29.4) |
Epiretinal membrane | 3 (17.6) |
Optic disc edema | 4 (23.5) |
Ocular hypotony or phthisis | 2 (11.8) |
Retinal detachment | 1 (5.9) |
Amblyopia | 1 (5.9) |
Active arthritis | 11 (64.7) |
Treatment history before baseline, patients | |
Methotrexate | 16 (94.1) |
Cyclosporine | 5 (29.4) |
Mycophenolate mofetil | 5 (29.4) |
Leflunomide | 1 (5.9) |
Azathioprine | 7 (41.2) |
Infliximab | 13 (76.5) |
Adalimumab | 7 (41.2) |
Etanercept | 2 (11.8) |
Rituximab | 1 (5.9) |
Golimumab | 7 (41.2) |
Treatment at baseline, patients | |
Topical corticosteroids | 14 (82.4) |
Systemic corticosteroids | 7 (41.2) |
Methotrexate | 10 (58.8) |
Cyclosporine | 2 (11.8) |
Leflunomide | 4 (23.5) |
Infliximab | 2 (11.8) |
Adalimumab | 4 (23.5) |
Abatacept | 3 (17.6) |
↵* Age at the time of starting TCZ therapy. TCZ: tocilizumab; JIA: juvenile idiopathic arthritis; ILAR: International League of Associations for Rheumatology; ANA: antinuclear antibodies; RF: rheumatoid factor.